Quick Answer
MADRIGAL PHARMACEUTICALS, INC. reported Operating Income of -$300.10 million for fiscal year 2025.
MADRIGAL PHARMACEUTICALS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$300.10M | +39.7% |
| 2024 | -$497.88M | -30.8% |
| 2023 | -$380.50M | -29.6% |
| 2022 | -$293.57M | -21.1% |
| 2021 | -$242.48M | -17.3% |
| 2020 | -$206.67M | -117.6% |
| 2019 | -$94.97M | -133.4% |
| 2018 | -$40.68M | -26.9% |
| 2017 | -$32.06M | -27.1% |
| 2016 | -$25.22M | -680.2% |
| 2015 | -$3.23M | +96.1% |
| 2014 | -$83.95M | +4.1% |
| 2013 | -$87.56M | -43.7% |
| 2012 | -$60.94M | -34.1% |
| 2011 | -$45.43M | -23.1% |
| 2010 | -$36.90M | -146.5% |
| 2009 | $79.30M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$113.97M | +2.0% | -141.5% |
| June 30, 2025 | -$47.20M | +71.0% | +40.5% |
| March 31, 2025 | -$79.31M | +47.8% | +31.8% |
| September 30, 2024 | -$116.30M | -18.0% | +28.4% |
| June 30, 2024 | -$162.54M | -88.0% | -6.9% |
| March 31, 2024 | -$152.04M | -94.1% | -54.3% |
| September 30, 2023 | -$98.53M | -22.5% | -14.0% |
| June 30, 2023 | -$86.45M | -23.0% | -10.4% |
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +39.7% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, MADRIGAL PHARMACEUTICALS, INC.’s operating income has declined by 478.4% (from $79.30 million to -$300.10 million).
- The most recent figure is from MADRIGAL PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: